Excellence is just the beginning.

Translate

French German Italian Portuguese Russian

Radiation Therapy Treatment Study for Stage III-IV Prostate Cancer

Clinical Trial Title: 
A phase II, double-blinded, placebo-controlled randomized trial of salvage radiotherapy with or without enhanced anti-androgen therapy with apalutamide in recurrent prostate cancer.
Clinical Trial Protocol ID: 
18073007
Clinical Trial Investigator Name: 
Dian Wang, MD, PhD
Clinical Trial Protocol Description: 

This phase II trial studies how well radiation therapy with or without apalutamide works in treating patients with stage III-IV prostate cancer. Radiation therapy uses high energy X-ray to kill tumor cells and shrink tumors. Androgen can cause the growth of prostate cancer cells. Drugs, such as apalutamide, may lessen the amount of androgen made by the body. Giving radiation therapy and apalutamide may work better at treating prostate cancer than radiation alone.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Have pathologically (histologically) proven diagnosis of prostate adenocarcinoma.
  • Have a history/physical exam within 90 days prior to Step 1 registration.

This is a partial list of elgibility requirements.

Clinical Trial Area: 
Genitourinary Cancers
Contact Phone: 
(312) 942-8892
Contact Name: 
Jean Gibson, RN